

Table S1. Demographic and clinical findings of patients with periorbital involvement during the course of mycosis fungoides (MF)

Case	Sex/Ethnicity	Age ^a	Age ^b	Cancers/skin diseases	Stage ^c	Stage ^d	Folliculotropism	LCT/CD30 ⁺	Treatment for periorbital lesions	Clinical outcome
1	F/Caucasian	76	76	CLL/No	IIB	IIB	No	Present/ Present	12 Gy in 6 fractions local radiotherapy to periorbital regions TSEB 12 Gy PUVA 2 times per week on shut eyes	Alive. Complete resolution of periorbital involvement. Duration of response to last follow-up: 124 days
2	F/Asian	66	74	Pleomorphic adenoma of the parotid gland/No	IB	IIB	Present	Present/ Present	PUVA once a week, Desonide 0.05%	Alive. Active disease no resolution of periorbital involvement at 1 year follow-up.
3	F/Hispanic	52	67	No/No	IIB	IIB	Present	Present/ Present	8 Gy in 4 fractions local radiation to periorbital regions 24 Gy in 12 fractions local radiation to periorbital regions	Alive. Persistent eye lesions at 3 months follow-up. Deceased.
4	F/Caucasian	66	68	No/No	NA	IB	Present	No/No		Alive. Complete resolution of periorbital involvement. Duration of response to last follow-up: 566 days
5	M/Caucasian	67	67	No/Favre-Racouchot Syndrome	IA	IA	Present	No/No		Deceased.
6	F/Caucasian	57	57	No/Psoriasis	IIB	IIB	No	Present/ Present	-	Alive. Complete resolution of periorbital involvement. Duration of response to last follow-up: 999 days.
7	F/Caucasian	56	56	No/No	IIA	IA	Present	Present/ Present	30 Gy in 17 fractions local radiation to periorbital regions	Deceased.

^aAge at diagnosis of MF, ^bAge at diagnosis of periorbital MF, ^cStage at diagnosis of MF, ^dStage at diagnosis of periorbital MF.

CLL: chronic lymphatic leukemia; Gy: gray; LCT: large cell transformation; PUVA; psoralen ultraviolet A.